Are Indoco Remedies latest results good or bad?

Indoco Remedies has reported its financial results for the quarter ending June 2025, showcasing a notable achievement in net sales, which reached Rs 437.89 crore, marking the highest quarterly sales in the last five quarters. This reflects a quarter-on-quarter growth of 12.22%, contrasting with the previous quarter's decline. However, the company's profitability metrics reveal significant challenges. The profit before tax (PBT) for the quarter was recorded at Rs -38.29 crore, indicating a substantial decline compared to the average PBT of the prior four quarters. Similarly, the profit after tax (PAT) also fell dramatically to Rs -35.79 crore, reflecting a considerable decrease from previous averages. Additionally, Indoco Remedies experienced a notable rise in interest expenses, which increased by 45.27% quarter on quarter to Rs 26.12 crore. This increase in interest costs suggests a higher level of borrowings, contributing to a debt-equity ratio of 0.97 times, the highest in the last five half-yearly periods. Overall, while the company has achieved a record in sales, the ongoing challenges in profitability and rising operational costs indicate a complex financial landscape. The company saw an adjustment in its evaluation, reflecting these mixed results.